{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.55","value":"74.23"},{"groupId":"OG001","spread":"19.66","value":"76.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"381"},{"groupId":"OG001","value":"408"}],"units":"Participants"}],"title":"Baseline (Cycle 1, Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.70","value":"-4.80"},{"groupId":"OG001","spread":"18.24","value":"-7.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"385"}],"units":"Participants"}],"title":"Change from baseline: Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.37","value":"-5.64"},{"groupId":"OG001","spread":"19.62","value":"-7.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"331"}],"units":"Participants"}],"title":"Change from baseline: Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.25","value":"-4.41"},{"groupId":"OG001","spread":"17.49","value":"-3.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"Change from baseline: Cycle 4, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.20","value":"-6.97"},{"groupId":"OG001","spread":"16.23","value":"0.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Change from baseline: Cycle 12, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.30","value":"-3.03"},{"groupId":"OG001","spread":"13.56","value":"3.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Change from baseline: Cycle 20, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.68","value":"-18.67"},{"groupId":"OG001","spread":"20.53","value":"3.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Change from baseline: Cycle 28, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.67","value":"-15.58"},{"groupId":"OG001","spread":"25.52","value":"-20.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"title":"Change from baseline: Treatment Discont. Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"381"},{"groupId":"OG001","value":"408"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.","dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG001","title":"Atezolizumab"}],"paramType":"MEAN","populationDescription":"All randomized patients with non-missing baseline assessment and at least one non-missing post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Physical Functioning Scale","type":"SECONDARY","unitOfMeasure":"units of a scale"}